4-(4-amino-3-fluorophenyl)-1-isoindolinone | 765948-80-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 英文名称: 4-(4-amino-3-fluorophenyl)-1-isoindolinone
• 英文别名: 4-(4-Amino-3-fluorophenyl)-2,3-dihydroisoindol-1-one
• CAS: 765948-80-9
• 化学式: C₁₄H₁₁FN₂O
• 分子量: 242.253
• InChiKey: WWTURSMMGDWPSH-UHFFFAOYSA-N

物化性质

• 沸点：
  539.8±50.0 °C(Predicted)
• 密度：
  1.325±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  18
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  55.1
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  异氰酸间甲苯酯 、 4-(4-amino-3-fluorophenyl)-1-isoindolinone 在 N-甲基吗啉 作用下， 以 四氢呋喃 为溶剂， 生成 N-[2-fluoro-4-(1-oxo-2,3-dihydro-1H-isoindol-4-yl)phenyl]-N'-(3-methylphenyl)urea
  参考文献：
  名称：

  Isoindolinone ureas: a novel class of KDR kinase inhibitors

  摘要：

  A series of substituted isoindolinone ureas was prepared and evaluated for enzymatic and cellular inhibition of KDR kinase activity. Several of these analogs, such as 14c, are potent inhibitors of KDR both enzymatically (<50nM) and cellularly (less than or equal to100 nM). A 3D KDR/CDK2/MAP kinase overlay model with several structurally related tyrosine kinase inhibitors was used to predict the binding interactions of the isoindolinone ureas with the KDR active site. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.06.041
• 作为产物：
  描述：

  3-溴-2-甲基苯(甲)酰氯 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 ammonium hydroxide 、 N-溴代丁二酰亚胺(NBS) 、 四(三苯基膦)钯 、 potassium acetate 、 sodium carbonate 、 三乙胺 、 过氧化苯甲酰 作用下， 以 四氢呋喃 、 乙二醇二甲醚 、 N,N-二甲基甲酰胺 、 苯 为溶剂， 生成 4-(4-amino-3-fluorophenyl)-1-isoindolinone
  参考文献：
  名称：

  Isoindolinone ureas: a novel class of KDR kinase inhibitors

  摘要：

  A series of substituted isoindolinone ureas was prepared and evaluated for enzymatic and cellular inhibition of KDR kinase activity. Several of these analogs, such as 14c, are potent inhibitors of KDR both enzymatically (<50nM) and cellularly (less than or equal to100 nM). A 3D KDR/CDK2/MAP kinase overlay model with several structurally related tyrosine kinase inhibitors was used to predict the binding interactions of the isoindolinone ureas with the KDR active site. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.06.041

文献信息

• Isoindolinone kinase inhibitors
  申请人：Curtin L. Michael

  公开号：US20050026976A1

  公开（公告）日：2005-02-03

  Compounds having the formula are useful for inhibiting protein tyrosine kinases. The present invention also discloses methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.

  具有该公式的化合物对于抑制蛋白酪氨酸激酶是有用的。本发明还公开了制造这些化合物的方法、包含这些化合物的组合物以及使用这些化合物的治疗方法。
• ISOINDOLINONE KINASE INHIBITORS
  申请人：Matulenko Mark

  公开号：US20110275630A1

  公开（公告）日：2011-11-10

  Compounds having the formula: are useful for inhibiting protein kinases. The present invention also discloses methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.

  具有以下化学式的化合物：对于抑制蛋白激酶非常有用。本发明还公开了制备该化合物的方法，含有该化合物的组合物，以及使用该化合物的治疗方法。
• US7129260B2
  申请人：——

  公开号：US7129260B2

  公开（公告）日：2006-10-31
• [EN] ISOINDOLINONE KINASE INHIBITORS<br/>[FR] INHIBITEURS DE KINASES DE TYPE ISOINDOLINONE
  申请人：ABBOTT LAB

  公开号：WO2012061602A1

  公开（公告）日：2012-05-10

  Compounds having the formula (I) are useful for inhibiting protein kinases. The present invention also discloses methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.
• Isoindolinone ureas: a novel class of KDR kinase inhibitors
  作者：Michael L Curtin、Robin R Frey、H.Robin Heyman、Kathy A Sarris、Douglas H Steinman、James H Holmes、Peter F Bousquet、George A Cunha、Maria D Moskey、Asma A Ahmed、Lori J Pease、Keith B Glaser、Kent D Stewart、Steven K Davidsen、Michael R Michaelides

  DOI：10.1016/j.bmcl.2004.06.041

  日期：2004.9

  A series of substituted isoindolinone ureas was prepared and evaluated for enzymatic and cellular inhibition of KDR kinase activity. Several of these analogs, such as 14c, are potent inhibitors of KDR both enzymatically (<50nM) and cellularly (less than or equal to100 nM). A 3D KDR/CDK2/MAP kinase overlay model with several structurally related tyrosine kinase inhibitors was used to predict the binding interactions of the isoindolinone ureas with the KDR active site. (C) 2004 Elsevier Ltd. All rights reserved.